This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/3/2026
Hello, and welcome to the CoreSep Therapeutics Q3 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand has been raised. To withdraw your message, to withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. It is now my pleasure to introduce CFO Atabak Mokari.
Hello everyone. Good afternoon and thank you for joining us. Today we issued a press release announcing our financial results for the third quarter and providing a corporate update. A copy is available at courseup.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those which statements express or imply. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our revenue in the third quarter of 2026 was $340.5 million, a 33% increase from the second quarter and a 64% increase compared to the prior year period. Quorum and authorized generic revenue was $249.1 million. LaFerriere revenue was $91.4 million. We expect our growth to continue and are reiterating our 2026 revenue guidance of $1.1 to $1.2 billion. Net income was $126.8 million in the third quarter of 2026, compared to $43 million in the second quarter and $19.7 million in the prior year period. Our cash and investments at September 30 were $662 million, an increase of $118 million in the quarter. We acquired $44 million of our common stock in the third quarter pursuant to our stock repurchase program, the exercise of course of stock options, and the vesting of restricted stock rates. I will now introduce Justin Gunn, president of our endocrinology division. Justin assumed this role at the beginning of October. Prior to that, he was the vice president of sales for our oncology division. Justin has more than two decades experience as a biopharma executive in a variety of commercial roles, including the successful launch of nine products in multiple therapeutic areas. Dustin?
Thank you, Atabak. It's an exciting time to step into this new role. Over the past month, I've gotten to know many of my new colleagues in Corset's outstanding endocrinology team. The endocrinology division delivered another quarter of record revenue, an accomplishment that I'm pleased to announce but take no credit for. Its skilled professionals have also helped create the conditions that will fuel future growth. More physicians are prescribing our medicines, and more patients are benefiting from them from ever before. And at the same time, realizing the full potential of our business will take, as it always has, hard work, creativity, and perseverance. And I look forward to helping them lead that effort. Hypercortisolism remains underdiagnosed and undertreated. Our catalyst and momentum studies prove that hypercortisolism is far more prevalent than previously understood. and these landmark findings are poised to change diagnostic and treatment paradigms. Of course, it takes time to incorporate scientific advances into new standards of care. Articles in leading journals such as publications in diabetes care describing our catalyst results are invaluable first steps. But in my experience, the support of medical societies is required to really raise awareness among these busy physicians. So we were gratified that the American Diabetes Association cited are catalyst findings in its consensus 2026 report in the management of type 2 diabetes released in October. The report recommends screening for hypercortisolism in patients whose blood sugar remains high despite treatment with multiple glucose lowering medications. It states that the treatment of mifepristone reduced hemoglobin A1C substantially in these patients. The consensus report follows the American Association of Clinical Endocrinology's reference to Catalyst's findings and its guidance for the management of diabetes issued in March of this year. As the ADA and the ACE recommendations become incorporated into medical practice, more patients are gonna be screened, diagnosed, and treated for hypercortisolism. So as a result, we expect our current Cushing Syndrome business to generate at least two billion in annual revenue by the end of this decade, The availability of Relacoralin provided faster growth to between 3 and 5 billion in 2030. I'll now turn the call over to Roberto Vieira, President of our Oncology Division.
You're reading a preview of the CORT Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing